Is Healthy Life overvalued or undervalued?

As of 7 November 2025, Healthy Life's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its market value. The company is currently assessed as undervalued, particularly when considering its PE ratio of 26.24, EV to EBITDA of 17.44, and ROCE of 13.87%. In comparison to its peers, Healthy Life's valuation metrics stand out; for instance, Hindustan Unilever has a PE ratio of 53.63 and Nestle India has a PE of 81.21, both categorized as very expensive.
Despite the recent downturn in stock performance with a year-to-date return of -66.81% compared to the Sensex's 6.50%, Healthy Life's attractive valuation suggests potential for recovery. The company's EV to Sales ratio of 0.50 further supports the argument for undervaluation, especially when juxtaposed against its peers, many of which exhibit significantly higher valuation multiples.